A3P Biomedical’s lead product is Stockholm3, a blood test that combines protein markers, genetic markers and clinical data with an advanced algorithm in order to detect aggressive prostate cancer at an early stage.
Early detection is the key to successful treatment of prostate cancer. Today the blood test prostate-specific antigen (PSA) is used. One problem with the PSA test is that it misses between 30 and 50 percent of all aggressive cases of cancer. Research shows that Stockholm3 finds 100 percent more aggressive cases of cancer. This improves the ability to detect and treat cancer at an early stage.
Another problem with the PSA test is that it cannot distinguish between aggressive and benign cancer. As a result, many men have to undergo unnecessary follow-up with a biopsy of the prostate. This can cause side effects such as sepsis as well as blood in the urine and feces. Research shows that Stockholm3 reduces the risk of conducting unnecessary prostate biopsies by 50 percent.
A third problem with the PSA test is that it is difficult to interpret. The Stockholm3 test provides an answer with a clear and easy-to-interpret recommendation. This makes it easier for the treating doctor to make a decision on potential further actions. It also helps the man to get a better understanding of his individual risk of getting prostate cancer. For example, nearly half of the men aged 50 to 70 years have a very low risk profile and do not need to take a new test until after six years.
Stockholm3 also reduces health care costs. Research shows that Stockholm3 reduces the direct costs by 17-28 percent.
The Stockholm3 test has been developed by Henrik Grönberg, professor of cancer epidemiology, and his team at Karolinska Institutet (KI) in Stockholm. Nearly 60,000 men participated in STHLM3, a clinical study which was conducted at KI between 2012 and 2015. The results were published in The Lancet Oncology in 2015. The results were clinically validated on over 20,000 men in Sweden, Norway, Germany, the Netherlands and the United Kingdom between 2016 and 2018.
Several healthcare providers in Sweden and Norway have already replaced the PSA test with the Stockholm3 test.